ArticleBlood2021
Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 35 citations in OpenAlex.
- Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook.Nanomaterials (Basel, Switzerland) · 2026Review
- The symbiotic axis between the acidic tumor microenvironment and cancer stem cells: a driver of malignancy and therapeutic resistance.Frontiers in oncology · 2026Review
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
- Targeting the pentose phosphate pathway mitigates graft-versus-host disease by rewiring alloreactive T cell metabolism.JCI insight · 2025Article
- T Cell immune reconstitution after allo-HSCT: key factors and implications.Blood science (Baltimore, Md.) · 2025Review
- Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.Transplantation · 2025Review
- Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse.BMC medicine · 2025Article
- Glycolysis: An early marker for vancomycin-specific T-cell activation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024Article
- Overview and progress of X-nuclei magnetic resonance imaging in biomedical studies.Magnetic resonance letters · 2023Review
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- In vivo deuterium magnetic resonance imaging of xenografted tumors following systemic administration of deuterated water.Scientific reports · 2023Article
- Imaging immunomodulatory treatment responses in a multiple sclerosis mouse model using hyperpolarizedCommunications medicine · 2023Article
- In vivo deuterium magnetic resonance imaging of xenografted tumors following systemic administration of deuterated water.Research square · 2023Article
- Article
- Cellular metabolism hijacked by viruses for immunoevasion: potential antiviral targets.Frontiers in immunology · 2023Review
- Review
- Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Frontiers in immunology · 2022Article
- Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?Frontiers in pediatrics · 2022Review
- Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.PloS one · 2022Article
- Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Graft-versus-host disease (GVHD) is a prominent barrier to allogeneic hematopoietic stem cell transplantation (AHSCT). Definitive diagnosis of GVHD is invasive, and biopsies of involved tissues pose a high risk of bleeding and infection. T cells are central to GVHD pathogenesis, and our previous studies in a chronic GVHD mouse model showed that alloreactive CD4+ T cells traffic to the target organs ahead of overt symptoms. Because increased glycolysis is an early feature of T-cell activation, we hypothesized that in vivo metabolic imaging of glycolysis would allow noninvasive detection of liver GVHD as activated CD4+ T cells traffic into the organ. Indeed, hyperpolarized 13C-pyruvate magnetic resonance imaging detected high rates of conversion of pyruvate to lactate in the liver ahead of animals becoming symptomatic, but not during subsequent overt chronic GVHD. Concomitantly, CD4+ T effector memory cells, the predominant pathogenic CD4+ T-cell subset, were confirmed to be highly glycolytic by transcriptomic, protein, metabolite, and ex vivo metabolic activity analyses. Preliminary data from single-cell sequencing of circulating T cells in patients undergoing AHSCT also suggested that increased glycolysis may be a feature of incipient acute GVHD. Metabolic imaging is being increasingly used in the clinic and may be useful in the post-AHSCT setting for noninvasive early detection of GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.